A biopharmaceutical company developing proteins therapeutics for cancers and orphan diseases.

Celgene will make an upfront payment to Acceleron of $25 million. Related StoriesUnique, tiny protein cage developed to deliver chemotherapy chemicals right to tumor cellsUnderstanding how schizophrenia impacts workings of the brainDiscovery could offer clues to how some viruses control expression of genetic materials’Acceleron has uncovered a thrilling new approach to treating disorders of erythropoiesis, and we are pleased to broaden our successful partnership with Celgene,’ said John Knopf, Ph.D., CEO of Acceleron.Related StoriesScientists discover little molecule that can block development of BRCA-deficient malignancy cellsBreastfeeding may not protect against allergiesNew research displays siblings of children with food allergies have sensitivity, however, not true Arterburn allergyLinda, PhD, formerly Vice President, Preclinical Development and Plan Management, provides been promoted to Vice President of Development at Alba. To joining Alba in March 2007 Prior, Dr. Arterburn was Executive Director of Discovery Study at Martek Biosciences. In this capability, she initiated an swelling research system and was lead inventor on two patents regarding novel anti-inflammatory lipids.